Abstract
Johnson & Johnson will release third-quarter results on October 13, 2026 Pre-MKt; the quarter is projected to deliver revenue growth near mid-single digits with softer adjusted EPS, while investors focus on Innovative Medicine momentum, MedTech execution, and the path for margins.Market Forecast
Consensus for the current quarter points to revenue of 25.22 billion US dollars, up 6.21% year over year, adjusted EPS of 2.59 (down 6.23% year over year), and EBIT of 7.50 billion US dollars (down 6.02% year over year). Forecasts for gross margin and net profit margin are not disclosed; the company’s guidance framework and market tracking imply modest top-line expansion and a mix-driven earnings step-down from last year’s comparable base.Innovative Medicine remains the primary engine and is expected to carry the growth load given ongoing oncology, immunology, and neuroscience contributions, supported by recent late-stage and real-world evidence updates across key assets. The most promising near-term opportunity set is linked to MedTech’s cardiovascular and surgical platforms; last quarter MedTech delivered 8.93 billion US dollars in revenue, and while a formal year-over-year breakdown was not disclosed, management commentary and product cadence indicate momentum consistent with the company’s mid-single-digit growth profile.
Last Quarter Review
In the prior quarter, Johnson & Johnson reported revenue of 25.31 billion US dollars (up 6.60% year over year), a gross profit margin of 68.33%, GAAP net profit attributable to shareholders of 5.53 billion US dollars with a net profit margin of 21.86%, and adjusted EPS of 2.90 (up 4.69% year over year). A notable financial highlight was a modest upside versus estimates in both revenue and adjusted EPS, with adjusted EPS beating by approximately 0.05 per share and EBIT growing 6.58% year over year. Within the business mix, Innovative Medicine contributed 16.38 billion US dollars and MedTech contributed 8.93 billion US dollars, representing roughly 64.73% and 35.27% of company revenue respectively, while the quarter-on-quarter growth rate of net profit was 5.71%.Current Quarter Outlook
Main business trajectory: Innovative Medicine
Innovative Medicine is positioned to sustain the company’s revenue trajectory this quarter, underpinned by oncology, immunology, and neuroscience assets that continue to expand usage and benefit from supportive data updates. Recent clinical readouts and label dynamics provide context for durable growth, including positive updates in multiple myeloma combinations, advances in lung cancer regimens, and late-stage progress in central nervous system therapies. New and expanding indications are expected to broaden the eligible patient base, helping to offset price and access frictions in legacy immunology therapies and supporting steady volume gains across prioritized inline medicines.The near-term revenue profile is expected to be driven by continued adoption in oncology—particularly cell therapy and targeted therapeutics—and by high-quality dermatology and immunology contributions, including the early commercial footprint of Icotyde in moderate-to-severe plaque psoriasis. Management emphasis on disciplined launch execution and channel mix also matters for margin trajectory; while the topline is projected to expand at a mid-single-digit rate, mix from newer launches and investment to scale these assets is likely to temper adjusted EPS year over year, consistent with consensus. Currency is a secondary factor for the quarter, but pricing, patient flow dynamics, and access pathways remain influential in shaping quarterly cadence for Innovative Medicine.
In aggregate, the segment’s growth prospects this quarter reflect a balance of volume-led expansion in oncology and immunology, continued life-cycle management on key therapies, and targeted investments in launch infrastructures. The company’s portfolio breadth reduces reliance on any single product, and ongoing clinical milestones across late-stage programs aim to create follow-on growth vectors into 2027. In the short run, consensus implies that Innovative Medicine will again account for the majority of incremental revenue, even as the earnings bridge absorbs increased R&D and commercial spend related to newer indications and launches.
Most promising opportunity set: MedTech cardiovascular and surgical platforms
MedTech’s cardiovascular and surgical franchises present the most visible opportunity set for incremental growth, with last quarter’s 8.93 billion US dollars of revenue reflecting healthy execution and a pipeline oriented toward higher-growth niches. The cardiovascular portfolio, including advanced heart recovery and intravascular lithotripsy platforms, benefits from procedure recovery trends and technology diffusion into additional geographies and care settings. The surgical ecosystem continues to evolve, with progress in robotics highlighted by the OTTAVA robotic surgical system meeting safety and performance endpoints in a gastric bypass study and supporting a De Novo submission that seeks a broad upper-abdominal indication.The projected growth algorithm for MedTech in the current quarter hinges on two levers: ongoing penetration of differentiated cardiovascular technologies in high-acuity settings and early platform expansion in soft-tissue robotics, which together can help counterbalance pricing pressure in more commoditized categories. The division’s margin path is sensitive to supply chain normalization, operating leverage from higher utilization, and the ramp pace of innovation platforms; while the company has not provided a MedTech-specific year-over-year forecast, product cadence and prior momentum indicate a profile consistent with the company’s mid-single-digit revenue growth outlook. The integration of robotics into operating room workflows, including design choices that address space constraints, should enhance adoption probability as regulatory milestones progress.
Taken together, MedTech’s near-term outlook is constructive: cardiovascular remains a steady growth contributor with a pipeline of innovation-driven procedures, and surgical robotics offers a tangible second growth leg pending regulatory clearance and subsequent commercialization. This segment mix, if executed as planned, has potential to underpin a sequential uptick in procedures and provide a cushion for earnings even if mix in Innovative Medicine tilts toward earlier-stage launches.
What could swing the stock this quarter
Three factors are likely to dominate how shares trade around the print and into subsequent sessions. First, the revenue/EPS shape versus consensus: with top-line growth estimated at 6.21% year over year and adjusted EPS forecast to decline 6.23%, an upside surprise on operating margin—or a smaller-than-expected EPS contraction—would be a positive stock driver, while any shortfall in revenue or incremental launch spend could pressure the print. Second, product news flow and clinical milestones: additional data updates for key oncology and immunology assets, as well as regulatory or platform progress in MedTech robotics, could influence sentiment disproportionately relative to near-term financials by reinforcing the pipeline’s durability.Third, legal and balance-sheet optics remain relevant to valuation. Notably, progress on legacy litigation has been cited by multiple institutions as reducing a prior overhang, an effect that could amplify the stock’s response to clean execution in the quarter. Investors will also watch cash conversion and capital return cadence following last quarter’s delivery, with attention to how working capital tracks the launch cycle and how management balances investment in growth platforms with shareholder returns. Within this backdrop, any refresh to the full-year framework—especially around revenue growth and the efficiency of scaling newer launches—may recalibrate expectations for 2027 earnings power.
Analyst Opinions
Across institutional commentary in the last six months, bullish views hold a clear majority relative to outright bearish calls, with several prominent houses reaffirming positive stances ahead of the print. The recurring themes in these bullish perspectives are consistent: momentum in Innovative Medicine anchored by oncology and immunology, the expanding commercial footprint for new assets such as Icotyde, the durability of cardiovascular growth in MedTech, and the diminishing impact of legacy legal overhangs on valuation multiples.RBC Capital maintained a Buy rating and cited the balance of dependable revenue growth with multiple levers to extend the cycle, noting execution progress in both segments while setting a price target of 287 US dollars. Morgan Stanley reiterated a Buy with a 294 US dollars target, emphasizing the combined contribution of oncology adoption curves and MedTech’s cardiovascular platforms to a steady mid-term growth algorithm, and highlighting that valuation still does not fully reflect pipeline optionality. Citi kept a Buy and raised its price target to 303 US dollars, pointing to the incremental impact of Icotyde and continued strength in oncology as supports for top-line resilience even as near-term EPS reflects mix and investment in launches.
Goldman Sachs reaffirmed a Buy with a 282 US dollars target, arguing that the gradual removal of historical overhangs and a clearer path for pipeline-driven growth improve the risk-reward heading into 2027. Scotiabank reiterated a Buy with a 305 US dollars target, underscoring that the breadth of late-stage programs and recent clinical wins should augment medium-term revenue visibility, while near-term results will likely reflect the natural step-up in commercial and R&D support for newer assets. Taken together, these bullish positions coalesce around the idea that the current quarter’s expected EPS dip is an investment phase rather than a secular profitability reset, and that the combined strength of Innovative Medicine and MedTech can deliver consistent mid-single-digit revenue growth with an improving free cash flow profile as launches scale.
Market-implied consensus aligns with this constructive stance: revenue is forecast at 25.22 billion US dollars, up 6.21% year over year, with adjusted EPS at 2.59 and EBIT at 7.50 billion US dollars. While specific forecasts for gross margin and net profit margin are not provided, the bullish camp expects that as the product mix normalizes and newer launches move along their adoption curves, operating leverage will begin to reassert and support a return to EPS growth. Importantly, the emphasis across these institutions remains on execution against a broad set of pipeline milestones—both in pharma and devices—that together set the stage for a more favorable earnings cadence after the current investment-heavy phase.
On balance, the majority view anticipates that Johnson & Johnson can deliver a quarter consistent with mid-single-digit top-line expansion, with clear signposts for improving profitability as the launch cohort matures. The stock’s near-term reaction will likely be driven by the interplay between reported margins and qualitative updates on the pipeline and regulatory timelines; however, the constructive institutional stance reflects confidence that the long-cycle drivers remain intact and continue to compound value over the medium term.